Boceprevir in chronic hepatitis C infection: A perspective review

Therapeutic Advances in Chronic Disease

Volumn 3, Issue 3, 2012, Pages 113-121

  Ascione, Antonio ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Boceprevir; Cost effectiveness; Efficacy; Genotype 1 infection; Hepatitis C virus; Peginterferon; Ribavirin

Indexed keywords

AMIODARONE; BEPRIDIL; BOCEPREVIR; BUPRENORPHINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIHYDROERGOTAMINE; ERGOTAMINE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHADONE; METHYLERGOMETRINE; MIDAZOLAM; ORAL CONTRACEPTIVE AGENT; PEGINTERFERON ALPHA2B; PIMOZIDE; PLACEBO; PROPAFENONE; QUINIDINE; RIBAVIRIN; RIFAMPICIN; VIRUS RNA;

ADVERSE OUTCOME; ANEMIA; ANTIVIRAL ACTIVITY; ANXIETY DISORDER; ARTHRALGIA; ASTHENIA; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; ENZYME INHIBITION; FATIGUE; FEVER; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; INHIBITION KINETICS; INJECTION SITE ERYTHEMA; INSOMNIA; IRRITABILITY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT INDICATION; VIROTHERAPY; VIRUS REPLICATION;

EID: 84868649787     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622312441496     Document Type: Review

References (36)

1. Alavian S.M. Tabatabaei S.V. Behnava B. (2012) Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis. J Viral Hepat 19: 88–93.
2. Alberti A. Ascione A. Colombo M. Craxì A. Piccinino F. Rizzetto M. Sarracino M. and the PROBE Study Group (2007) Pre-treatment factors predicting sustained virological response in treatment-naive HCV genotype 1 patients participating in a large, practice-based nationwide observational study. J Hepatol 46:(Suppl. 1):S215.
3. Almasio P.L. Niero M. Angioli D. Ascione A. Gullini S. Minoli G. et al. (2005) Experts’ opinions on the role of liver biopsy in HCV infection: a Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.). J Hepatol 43: 381–387.
4. Ascione A. de Luca M. Tartaglione M.T. Lampasi F. Di Costanzo G.G. Lanza A.G. et al. (2010) Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 138: 116–122.
5. Bacon B.R. Bruno S. Schiff E.R. Kwo P.Y. Buti M. Pedicone L. (2011) Predictors of sustained virologic response (SVR) among poor interferon (IFN) responders when boceprevir (BOC) is added to peginterferon alfa-2b/ribavirin (PR). Hepatology 54 (Suppl.):376A.
6. Bacon B.R. Gordon S.C. Lawitz E. Marcellin P. Vierling J.M. Zeuzem S. et al. (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364: 1208–1217.
7. Barnard R.J. Zeuzem S. Vierling J.M. Sulkowski M.S. Manns M.P. Long J. et al. (2011) Analysis of resistance-associated amino acid variants (RAVs) in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase 3 clinical studies. Hepatology 54 (Suppl.): 440A.
8. Boceprevir (2010) Drugs 10: 203–210.
9. Brillanti S. Mazzella G. Roda E. (2011) Ribavirin for chronic hepatitis C: and the mystery goes on. Dig Liver Dis 43: 425–430.
10. Bruno S. Vierling J.M. Esteban R. Nyberg L.M. Tanno H. Albrecht J.K. et al. (2011) Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype-1 with advanced fibrosis/cirrhosis: subgroup analysis of sprint-2 and respond-2 studies. J Hepatol 54 (Suppl. 1): S4.
11. Chhatwal J. Ferrante S.A. Dasbach E.J. El Khoury A. Brass C.A. Burroughs M. et al. (2011) Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon/ribavirin. Hepatology 54 (Suppl.): 801A.
12. Craxi A. Almasio P.L. Ingrassia D. Ascione A. Di Costanzo G.G. (2008) The natural history of HCV infection: a systematic review. In: Ed. Buti M. Esteban R. (eds), BC)VH Viral Hepatitis (pp. 250-266). Madrid: AG RUPEM S. Coop.
13. EASL (2011) Clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 55: 245–264.
14. Ferrante S.A. Chhatwal J. Elbasha E. Dasbach E.J. El Khoury A. Poordad F. et al. (2011) Cost-effectiveness of boceprevir based regimens in previously untreated adult subjects with chronic hepatitis C genotype 1. Hepatology 54 (Suppl.): 795A.
15. Flamm S.L. Lawitz E. Jacobson I.M. Bourliere M. Hezode C. Vierling J.M. et al. (2011) Overall safety profile of boceprevir (BOC) plus peginterferon alfa-2a/ribavirin in genotype 1 previous non-responders and relapsers to peginterferon/ribavirin. Hepatology 54 (Suppl.):838A.
16. Foote B.C. Spooner L.M. Belliveau P.P. (2011) Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother 45: 1085–1093.
17. Gordon S.C. Reddy K. McCone J. Jacobson I.M. Esteban R. Pedicone L. et al. (2011) Effect of baseline viral load (VL) on response to boceprevir (BOC) plus peginterferon alfa-2b/ribavirin (PR) in patients infected with HCV genotype 1. Hepatology 54 (Suppl.): 812A.
18. Halfon P. Locarnini S. (2011) Hepatitis C virus resistance to protease inhibitors. J Hepatol 55: 192–206.
19. Hofmann W.P. Chung T.L. Osbahr C. Susser S. Karey U. Mihm U. et al. (2011) Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir. Antivir Ther 16: 695–704.
20. Jacobson I.M. Marcellin P. Zeuzem S. Sulkowski M.S. Esteban R. Pedicone L. et al. (2011) Treatment week 12 / 24 stopping rules for boceprevir (BOC) combination therapy with peginterferon+ribavirin (PR): exploratory analyses of SPRINT- 2 and RESPOND-2. Hepatology 54 (4 Suppl): 808A.
21. Jensen D.M. (2011) A new therapy era of hepatitis C therapy begins. N Engl J Med 364: 1272–1274.
22. Jensen D.M. Ascione A. (2008) Future directions in therapy for chronic hepatitis C. Antivir Ther 13 (Suppl. 1): 31–36.
23. Kwo P.Y. Lawitz E.J. McCone J. Schiff E.R. Vierling J.M. Pound D. et al. (2010) Efficacy of boceprevir, an NS 3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376: 705–716.
24. Lawitz E. Poordad F. Bronowicki J. Marcellin P. Feinman V.S. Kwo P.Y. et al. (2011) The effect of using lower limit of quantitation (LLQ) vs lower limit of detection (LLD) for the definition of undetectable HCV RNA: data from the RESPOND-2 and SPINT-2 trials. Hepatology 54 (Suppl.): 442A.
25. Manns M.P. McCone J. Davis M. Shiffman M.L. Rossaro L. Bourliere M. et al. (2011) Safety benefits of response-guided therapy with boceprevir (BOC) plus peginterferon alfa – 2b/ribavirin (PR) in previously untreated patients with HCV genotype 1 infection. Hepatology 54 (Suppl.): 813A.
26. McHutchison J.G. Lawitz E.J. Shiffman M.L. Muir A.J. Galler G.W. McCone J. et al. (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580–593.
27. Ogert R.A. McMonagle P. Black S. Curry S. Guo Z. Lesburg C. et al. (2011) Genotypic and phenotypic correlates of resistance in HCV genotype 1a and 1b infected patients treated with boceprevir plus peginterferon alpha and ribavirin. Hepatology 54 (Suppl.): 794A.
28. Poordad F. Bronowicki J.-P. Gordon S.C. Zeuzem S. Jacobson I.M. Sulkowski M.S. et al. (2011 c) Il28b Polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (Boc) combination therapy. J Hepatol 54 (Suppl. 1): S6.
29. Poordad F. Lawitz E. Gordon S.C. Bourli M. Vierling J.M. Poynard T. et al. (2011 b) Concomitant medication use in patients with hepatitis c genotype 1 treated with boceprevir (BOC) combination therapy. Hepatology 54 (Suppl.): 799A.
30. Poordad F. McCone J. Jr Bacon B.R. Bruno S. Manns M.P. Sulkowski M.S. et al. (2011 a) Boceprevir for untreated chronic HCV genotype 1. N Engl J Med 364: 1195–1206.
31. Reddy K. Nunes F. Balart L.A. Sjogren R. Pedicone L. Burroughs M. et al. (2011) An evaluation of neutropenia in the pivotal studies of boceprevir (BOC) plus peginterferonalfa – 2b/ribavirin (PR). Hepatology 54 (Suppl.): 814A.
32. Rumi M.G. Aghemo A. Prati G.M. D'Ambrosio R. Donato M.F. Soffredini R. et al. (2010) Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 138: 108–115.
33. Stone J.A. Wenning L.A. Hang Y. Su J. Gupta S. Tsai K. et al. (2011) Assessment of Boceprevir pharmacokinetic / pharmacodynamic relationships for sustained viral response and occurrence of anemia from phase 3 data. Hepatology 54 (Suppl.): 993A.
34. Sulkowski M.S. Reddy K. Pedicone L. Shen J. Burroughs M. Brass C.A. et al. (2011) ITPA deficiency is associated with lower rates of anemia and EPO use in patients treated with boceprevir (BOC) plus peginterferon / ribavirin (PR). Hepatology 54 (Suppl.): 798A.
35. Victrelis (2011) Package insert. Merck & Co., Inc. Whitehouse Station, NJ, USA.
36. Vierling J.M. Flamm S.L. Gordon S.C. Lawitz E. Bronowicki J. Davis M. et al. (2011) Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: the PROVIDE study. Hepatology 54 (Suppl.): 796A.